Categories: Health

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

 | Source: RxSight, Inc.

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

RxSight’s management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

GlobeNews Wire

Recent Posts

Stamus Networks Marks 10th Year Supporting NATO CCDCOE Cyber Defense Exercises

Company celebrates a decade of supporting the world's premier live-fire cyber defense exercises with expertise,…

43 minutes ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

3 hours ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

3 hours ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus…

3 hours ago

GIGABYTE Unveils Next-Generation Gaming Peripherals with AORUS K10 INFINITY Keyboard and M10 INFINITY Mouse at COMPUTEX 2026

TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation…

3 hours ago

Nationwide Celebrations mark Ruskin Bond’s 92nd Birthday

GURUGRAM, India, June 2, 2026 /PRNewswire/ -- On May 19, 2026, 92 bookstores across India…

9 hours ago